Bank Of America Corp Allakos Inc. Transaction History

Bank Of America Corp

$1.06 Trillion
Q1 2024

A detailed history of Bank Of America Corp transactions in Allakos Inc. stock. As of the latest transaction made, Bank Of America Corp holds 529,616 shares of ALLK stock, worth $466,062. This represents 0.0% of its overall portfolio holdings.

Number of Shares

529,616

Previous 360,749 46.81%

Holding current value

$466,062

Previous $984,000 32.22%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.02 - $3.23 $172,244 - $545,440	168,867 Added 46.81%	529,616 $667,000
Q4 2023 Feb 14, 2024	SELL	$1.72 - $3.18 $37,277 - $68,920	-21,673 Reduced 5.67%	360,749 $984,000
Q2 2023 Aug 14, 2023	SELL	$3.6 - $5.25 $1.86 Million - $2.72 Million	-517,498 Reduced 57.5%	382,422 $1.67 Million
Q1 2023 May 12, 2023	BUY	$4.3 - $8.27 $1.9 Million - $3.66 Million	442,798 Added 96.87%	899,920 $4 Million
Q4 2022 Feb 10, 2023	BUY	$5.97 - $8.42 $2.01 Million - $2.83 Million	336,581 Added 279.23%	457,122 $3.85 Million

Q3 2022 Nov 14, 2022	SELL	$3.02 - $5.84 $209,823 - $405,751	-69,478 Reduced 36.56%	120,541 $737,000
Q2 2022 Aug 12, 2022	BUY	$2.6 - $6.14 $351,790 - $830,766	135,304 Added 247.29%	190,019 $594,000
Q1 2022 May 16, 2022	SELL	$5.08 - $9.81 $641,258 - $1.24 Million	-126,232 Reduced 69.76%	54,715 $312,000
Q4 2021 Feb 08, 2022	BUY	$8.55 - $111.89 $1.33 Million - $17.3 Million	155,029 Added 598.15%	180,947 $1.77 Million
Q3 2021 Nov 15, 2021	BUY	$76.53 - $110.43 $179,233 - $258,627	2,342 Added 9.93%	25,918 $2.74 Million
Q2 2021 Sep 13, 2021	BUY	$85.37 - $114.1 $2.01 Million - $2.69 Million	23,576 New	23,576 $2.01 Million

Others Institutions Holding ALLK

# of Institutions

103

Shares Held

77.2M

Call Options Held

70.7K

Put Options Held

2.8K

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $74.6M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Allakos Inc. Transaction History